Q1 2023 EPS Estimates for Curis, Inc. (NASDAQ:CRIS) Lifted by Analyst

Curis, Inc. (NASDAQ:CRIS – Get Rating) – Investment analysts at HC Wainwright upped their Q1 2023 EPS estimates for Curis in a research note issued to investors on Monday, March 13th. HC Wainwright analyst E. White now expects that the biotechnology company will post earnings per share of ($0.11) for the quarter, up from their previous estimate of ($0.12). The consensus estimate for Curis’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Curis’ Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.11) EPS, FY2023 earnings at ($0.42) EPS, FY2024 earnings at ($0.47) EPS and FY2025 earnings at ($0.50) EPS.

Separately, StockNews.com began coverage on shares of Curis in a report on Thursday. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Curis presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Curis Stock Up 6.2 %

Shares of Curis stock opened at $0.56 on Thursday. The firm’s 50 day moving average is $0.69 and its two-hundred day moving average is $0.74. Curis has a 52 week low of $0.47 and a 52 week high of $2.90. The firm has a market capitalization of $54.04 million, a P/E ratio of -0.92 and a beta of 2.88.

Curis (NASDAQ:CRIS – Get Rating) last posted its quarterly earnings results on Monday, March 13th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. Curis had a negative net margin of 557.68% and a negative return on equity of 87.74%. The company had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $3.03 million. During the same quarter in the previous year, the business posted ($0.15) EPS.

Institutional Investors Weigh In On Curis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Citigroup Inc. grew its holdings in Curis by 187,394.5% during the 4th quarter. Citigroup Inc. now owns 2,137,437 shares of the biotechnology company’s stock valued at $1,176,000 after buying an additional 2,136,297 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Curis during the 3rd quarter valued at $948,000. Nantahala Capital Management LLC grew its position in Curis by 46.4% during the second quarter. Nantahala Capital Management LLC now owns 3,628,162 shares of the biotechnology company’s stock valued at $3,572,000 after acquiring an additional 1,149,897 shares during the period. Renaissance Technologies LLC increased its stake in Curis by 81.5% during the second quarter. Renaissance Technologies LLC now owns 2,392,035 shares of the biotechnology company’s stock worth $2,355,000 after acquiring an additional 1,073,835 shares during the last quarter. Finally, Walleye Capital LLC increased its position in Curis by 3,036.1% during the 1st quarter. Walleye Capital LLC now owns 841,793 shares of the biotechnology company’s stock worth $2,003,000 after purchasing an additional 814,951 shares in the last quarter. 38.72% of the stock is currently owned by hedge funds and other institutional investors.

About Curis

(Get Rating)

Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.